The essential knowledge needed by angiologists and cardiologists treating vasculitis
Authors:
D. Karetová 1; R. Bečvář 2
Authors‘ workplace:
II. interní klinika kardiologie a angiologie
1. LF UK a VFN, Praha
1; Revmatologický ústav, Revmatologická klinika
2
Published in:
Kardiol Rev Int Med 2008, 10(2): 74-78
Overview
The vasculitides are complex, multisystemic diseases, the natural history of which has been modified by the use of efficient immunosuppressive drugs. The appropriate changes in therapy according to the disease activity is necessary to achieve optimal control of the process. Careful clinical observation supported by appropriate laboratory tests at all stages from diagnosis to long-term follow-up is mandatory. Routine monitoring for drug toxicity in the short- and long-term is also essential.
Key words:
immunosuppressants – small-vessel vasculitides – large-vessel vasculitides.
Sources
1.Brunton LL. The Pharmacological Basis of Therapeutics. 11 ed. New York: McGraw-Hill 2006: 1405-1433.
2.Harvey RA, Champe PC. Pharmacology. 3. ed. Philadelphia: Lippincott Williams and Wilkins 2006: 485-495.
3.Lamprecht P, Till A, Steinmann J et al. Current State of Biologicals in the Management of Systemic Vasculitis. Ann NY Acad Sci 2007; 1100: 261-270.
4.Yazici Y. Vasculitis Update, 2007. Bull NYU Hosp Jt Dis 2007; 65(3): 212-214.
5.Guillevin L, Pagnoux Ch. When Should Immunosuppressants Be Prescribed to Treat Systemic Vasculitides? Intern Med 2003; 42: 313-317.
6.Belmont HM. Treatment of ANCA-associated systemic Vasculitis. Bull NYU Hosp Jt Dis 2006; 64(1,2): 60-66.
7.Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-763.
8.Jayne DR, Renault VL, Lockwood CM. Anca anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993; 6: 207-219.
9.Rieu V, Cohen P, André MH et al. Characteristics and outcome of 49 patients with symptomatic cryoglobulinemia. Rheumatology 2002; 41: 290-300.
10.Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteriitis. Clin Exp Rheumatol 2003; 21(suppl 32): S29-S34.
11.Jover JA, Hernandez-Garcia C, Morado IC et al. Combined treatment of giant cell arthritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
12.Salvarani C, Macchioni PL, Manzini C et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med 2007; 146: 631-639.
13.Nesjet G, Berkun Y, Mates M et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arthritis. Arthritis Rheum 2004; 50: 1332-1337.
14.Danech-Meyer HV, Savino PJ. Giant cell arthritis. Curr Opin Ophtalmol 2007; 18: 443-449.
15.Spiera RF, Spiera H. Therapy for Giant Cell Arteritis: Can We Do Better? Arthritis Rheum 2006; 54: 3071-3074.
16.Rav-Acha M, Plot L, Peled N et al. Coronary involvement in Takayasu's arteritis. Autoimmun Rev 2007; 6(8): 566-571.
17.Tesař V. Systémové vaskulitidy. Angiologie pro praxi. 2. ed. Praha: Maxdorf 2007: 160-177.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2008 Issue 2
Most read in this issue
- The essential knowledge needed by angiologists and cardiologists treating vasculitis
- Post-stroke rehabilitation
- Cardiovascular diseases in pregnancy
- The treatment of acute myocardial infarction by combination of prehospital administered tenecteplase and acute PCI